Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Stem cell therapy

- PMLiVE

Spinal stimulation implant offers new hope for Parkinson’s disease treatment

The implant was tested to correct gait disorders associated with advanced cases of the disease

- PMLiVE

FDA grants fast track designation to AviadoBio’s dementia gene therapy

The regulator has also given clearance for the candidate to be studied in frontotemporal dementia patients

- PMLiVE

New UK research institute launched for motor neurone disease

The research institute will bring together MND labs, clinical centres and researchers

- PMLiVE

Alzheimer’s Research UK survey highlights dementia knowledge gaps

The UK poll revealed that only 60% of adults know that dementia is a cause of death

- PMLiVE

Study reveals cancer drug could be used to treat inflammatory diseases

Researchers plan to test the drug against inflammatory diseases in clinical trials

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

Alzheimer’s Society raises concerns over undiagnosed young-onset dementia cases

The UK charity estimates that over 19,000 people in England are living without a diagnosis

- PMLiVE

New Swedish study finds HSCT can slow progression of multiple sclerosis

More than 70% of participants in the study had no new progression after five years of treatment

- PMLiVE

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

Approximately 2.5 million people worldwide are affected by the neurological disease

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

Differences in immune responses could optimise future COVID-19 vaccines

Vulnerability to different mutations was linked to previous infections and vaccination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links